-
3-Bromopyruvate and Cetuximab Synergy Reverses CRC Drug Resi
2026-05-03
This study demonstrates that 3-bromopyruvate (3-BP) sensitizes cetuximab-resistant colorectal cancer (CRC) cells to therapy by triggering autophagy-dependent ferroptosis and apoptosis. Mechanistic insights reveal FOXO3a pathway restoration as a key mediator, offering new strategies to overcome resistance in KRAS/BRAF-mutant and acquired-resistant CRC models.
-
Iron Stress Alters Enterocyte Metabolism and Inflammatory Si
2026-05-02
Navazesh and Ji's 2025 study reveals that iron deficiency and excess profoundly reprogram enterocyte metabolism and inflammatory gene expression in IPEC-J2 cells. These findings clarify the cellular basis of iron imbalance effects on intestinal health, with implications for both nutritional interventions and disease modeling.
-
α-Amanitin in Transcriptional Regulation: Applied Workflows
2026-05-01
α-Amanitin from APExBIO empowers researchers to dissect RNA polymerase II function and chromatin dynamics with precision. This in-depth guide walks through validated protocols, troubleshooting, and the latest breakthroughs in oocyte development and gene expression pathway analysis.
-
JNJ-26854165 (Serdemetan): Applied Workflows in Cancer Resea
2026-05-01
JNJ-26854165 (Serdemetan) empowers cancer researchers to robustly modulate the p53 pathway, enabling precise anti-proliferative and apoptosis studies with reliable, quantifiable outcomes. This guide details best-practice experimental set-ups, troubleshooting strategies, and actionable insights for maximizing data reliability when using APExBIO's Serdemetan in vitro and in vivo.
-
SP2509: Lysine-Specific Demethylase 1 Antagonist in AML Rese
2026-04-30
SP2509 enables precise modulation of cancer epigenetics by selectively antagonizing LSD1, making it an indispensable tool for acute myeloid leukemia (AML) research. This article delivers actionable workflows, advanced troubleshooting, and translational insights that maximize the value of SP2509 in both in vitro and in vivo models.
-
GLP-1 (9-36) Amide: Optimizing GLP-1 Receptor Antagonist Stu
2026-04-30
GLP-1 (9-36) amide unlocks robust, reproducible interrogation of GLP-1 receptor signaling in metabolic and diabetes research. This guide delivers actionable workflows, troubleshooting insights, and evidence-based protocol refinements tailored to maximize the antagonist’s selectivity, stability, and data reliability.
-
Translating Lipid Hydrolysis Inhibition: CAY10499 in Modern
2026-04-29
This thought-leadership article explores the frontier of lipid metabolism research, focusing on the mechanistic and translational impact of CAY10499—a potent inhibitor of human hormone sensitive lipase and monoglyceride lipase. Bridging recent discoveries in extracellular vesicle-driven macrophage differentiation in hepatocellular carcinoma with the expanding potential of selective lipase inhibitors, the article guides translational researchers on strategic assay deployment, biomarker exploration, and the future landscape of immunometabolic intervention.
-
Apicidin as a Histone Deacetylase Inhibitor: Optimizing Assa
2026-04-29
Harness Apicidin's selectivity as an HDAC3/6 inhibitor for advanced epigenetic and anti-proliferative research. This guide translates cutting-edge reference findings into actionable workflows, troubleshooting strategies, and a nuanced view of Apicidin’s dual role as both a research tool and emerging environmental mycotoxin.
-
QPRT Drives Breast Cancer Invasion via P2Y11 and Myosin Phos
2026-04-28
This study reveals that quinolinate phosphoribosyltransferase (QPRT) promotes breast cancer cell invasiveness by enhancing myosin light chain phosphorylation through purinergic (P2Y11 receptor-mediated) signaling. The findings highlight QPRT as a potential prognostic indicator and therapeutic target, and demonstrate that P2Y11 antagonists can suppress QPRT-driven migration phenotypes in breast cancer models.
-
GSK J4 HCl: JMJD3 Inhibitor Empowering Epigenetic Regulation
2026-04-28
GSK J4 HCl stands out as a cell-permeable JMJD3 inhibitor, enabling researchers to dissect chromatin dynamics and inflammation pathways with quantitative precision. Its unique ethyl ester structure ensures robust cellular uptake, driving reproducible results in both immune modulation studies and pediatric glioma models.
-
APEX2 Is Essential for TERT Expression in Human Stem Cells
2026-04-27
The referenced study identifies apurinic/apyrimidinic endodeoxyribonuclease 2 (APEX2) as a novel regulator required for efficient expression of telomerase reverse transcriptase (TERT) in human embryonic stem cells (hESCs). This work reveals mechanistic links between DNA repair machinery and telomerase regulation, with implications for stem cell maintenance, aging, and cancer biology.
-
PTGER4-Driven HDAC Modulation and SPINK4 Regulation in Recta
2026-04-27
Anbazhagan et al. (2024) dissect the PTGER4 signaling pathway in rectal epithelial cells, revealing how mesenchymal stromal cell-derived PGE2 modulates class IIa HDAC activity and SPINK4 expression. This work clarifies molecular links between epithelial barrier regulation and mucosal injury response, offering new mechanistic insights for gastrointestinal research.
-
Tioconazole: Bridging Ergosterol Pathways and Translational
2026-04-26
This article delivers a thought-leadership perspective on Tioconazole in antifungal drug development, weaving mechanistic insights on ergosterol biosynthesis inhibition with strategic recommendations for translational researchers. By contextualizing APExBIO’s Tioconazole within the metabolic-genomic landscape, it provides actionable guidance for robust fungal infection modeling, resistance research, and protocol reproducibility. The discussion integrates recent findings on metabolic regulation of DNA repair, offering a cross-disciplinary framework that expands beyond standard product literature.
-
Improving In Vitro Assessment of PARP Inhibitors in Cancer R
2026-04-25
Schwartz's dissertation systematically dissects how in vitro methods can more accurately differentiate between proliferative arrest and cell death in response to anti-cancer agents. Her work highlights the importance of distinguishing these effects when evaluating novel PARP inhibitors, providing a more nuanced basis for translational research and preclinical drug development.
-
RepSox ALK5 Inhibitor: Enhancing iPSC Platelet Differentiati
2026-04-24
RepSox, a potent ALK5 inhibitor from APExBIO, empowers researchers to streamline induced pluripotent stem cell (iPSC) differentiation workflows for scalable, cost-effective platelet production. Discover how protocol optimizations unlock higher megakaryocyte and platelet yields, and learn best practices for troubleshooting TGF-β pathway inhibition.